ALX Oncology Holdings Inc (NAS:ALXO)
$ 8.43 -0.09 (-1.06%) Market Cap: 439.20 Mil Enterprise Value: 297.20 Mil PE Ratio: 0 PB Ratio: 2.61 GF Score: 34/100

ALX Oncology Holdings Inc SITC 2021 Conference Call Transcript

Nov 09, 2021 / 01:00PM GMT
Release Date Price: $40.93 (-21.47%)
Operator

Good morning, and welcome to the ALX Oncology Conference Call. (Operator Instructions) I will turn the call over to Jeanne Jew, Chief Business Officer of ALX Oncology. Jeanne.

Jeanne Y. Jew
ALX Oncology Holdings Inc. - Chief Business Officer

Good morning, and thank you for dialing in today's conference call. I'm Jeanne Jew, Chief Business Officer of ALX Oncology. Today's call will focus on clinical data of Evorpacept, a CD47 myeloid checkpoint inhibitor and specifically, data from our ASPEN-01 Phase Ib trial in gastric cancer and head and neck cancer that will be presented at the Society for Immunotherapy of Cancer or SITC on November 13.

A slide deck for this webcast is available on our website in the Investors Events section. Dr. Sophia Randolph, our Chief Medical Officer, will discuss the updated Phase Ib gastric cancer combination data. We are also privileged to be joined today by Dr. Kevin Harrington, Professor of Biological Cancer Therapies and Head of the Division of radiotherapy and imaging at the Institute of Cancer Research, who will discuss

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot